A Phase 2A Randomized, Placebo Controlled Trial of EPI-743 in Children with Rett Syndrome.

Trial Profile

A Phase 2A Randomized, Placebo Controlled Trial of EPI-743 in Children with Rett Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2015

At a glance

  • Drugs Vatiquinone (Primary)
  • Indications Rett syndrome
  • Focus Therapeutic Use
  • Sponsors Edison Pharmaceuticals
  • Most Recent Events

    • 03 Sep 2014 Primary endpoint has not been met (Rett Syndrome Clinical Severity Score, change at six months from baseline), as reported in an Edison Pharmaceuticals media release.
    • 03 Sep 2014 Results published in an Edison Pharmaceuticals media release.
    • 14 Dec 2013 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top